Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Reporting Period: Quarterly period ended June 30, 2006 (Form 10-Q)
Business Model: A development-stage nanotechnology company commercializing products through majority-owned subsidiaries and university partnerships. The company operates via an Outsourced R&D Program, a Commercialization Program (subsidiaries), and a Patent Toolbox.
Key Subsidiaries: Aonex Technologies (semiconductors), Insert Therapeutics (drug delivery), Calando Pharmaceuticals (RNAi therapeutics), and NanoPolaris/Unidym (nanotube electronics).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 |
Nine Months Ended June 30, 2006 |
Nine Months Ended June 30, 2005 |
|---|---|---|---|
| Revenue | $246,229 | $556,229 | $380,408 |
| Operating Expenses | $4,729,227 | $13,037,109 | $6,520,586 |
| Operating Loss | $(4,482,998) | $(12,480,880) | $(6,140,178) |
| Net Loss | $(3,974,148) | $(10,217,686) | $(3,981,518) |
| Cash and Cash Equivalents | $16,688,051 | $16,688,051 | $22,467,016 (Sep 30, 2005) |
| Marketable Securities | $13,945,260 | $13,945,260 | $76,880 (Sep 30, 2005) |
| Total Assets | $40,582,772 | $40,582,772 | $29,040,721 (Sep 30, 2005) |
| Accumulated Deficit | $(19,696,796) | $(19,696,796) | $(9,479,110) (Sep 30, 2005) |
Liquidity: As of June 30, 2006, the company held approximately $30.6 million in cash and marketable securities. Management believes this is sufficient to fund operations beyond the end of fiscal year 2007.
Material Changes vs. Prior Period
- Net Loss Increase: The nine-month net loss increased to $10.2 million from $4.0 million in the prior year. This increase is primarily due to higher staffing costs, legal fees related to capital raises and acquisitions, and significant R&D expenses for subsidiary clinical trial preparations.
- Revenue Growth: Revenue for the nine months ended June 30, 2006, increased to $556,229 from $380,408 in the prior year, driven by development fees and grant income (e.g., SBIR grants and Calando licensing fees).
- Expense Drivers:
- Salaries & Wages: Increased 191% year-over-year (three months) due to hiring for Sarbanes-Oxley compliance, executive management, and technical staff.
- Stock-Based Compensation: Increased significantly due to the retrospective adoption of SFAS 123R and new option grants.
- Patent Expenses: Increased 1,240% (three months) largely due to accruals for Caltech patent applications.
- Investing Activities: Significant cash outflows for purchasing marketable securities ($18.6 million) and capital contributions to subsidiaries (Calando, NanoPolaris, Insert).
Guidance, Outlook, and Risks
- Outlook: The company does not expect product sales revenue in fiscal year 2006. Losses are expected to increase as subsidiaries continue development and clinical trials.
- Capital Commitments:
- Calando Pharmaceuticals: Committed to provide up to $7 million in additional capital subject to milestones.
- NanoPolaris/Unidym: Committed to provide up to $4 million in additional capital subject to milestones.
- Key Developments:
- Insert Therapeutics received FDA approval for its Investigational New Drug (IND) application for IT-101 (anti-cancer) and began Phase I clinical trials.
- NanoPolaris acquired the net assets and name of Unidym, Inc., and changed its name to Unidym, Inc.
- New collaboration announced with the University of Florida for flexible thin film electronic devices.
- Risks:
- Development Stage: No products are currently ready for sale; success of commercialization is uncertain.
- Liquidity: Continued reliance on equity financing, grants, and collaborations to fund operations.
- Executive Departure: Mr. Leon Ekchian stepped down as President and Director; a severance agreement totaling approximately $379,000 was accrued.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $30.6 million cash position against the committed $11 million in future capital contributions to subsidiaries and ongoing operating losses.
- Stock-Based Compensation: Review the impact of SFAS 123R adoption on reported losses and the dilution potential of outstanding options (4.6 million) and warrants (1.4 million).
- Subsidiary Milestones: Monitor the progress of Insert Therapeutics' Phase I clinical trials for IT-101 and Calando's RNAi therapeutics, as these are critical for future revenue and capital commitment triggers.
- Revenue Quality: Assess the sustainability of revenue streams, which are currently derived from grants, development fees, and licensing rather than product sales.
- Executive Transition: Evaluate the impact of the President's departure and the new management team's ability to execute the commercialization strategy.